New kinase and HDAC hybrid inhibitors: recent advances and perspectives

Area of Science:

• Medicinal Chemistry
• Oncology
• Drug Discovery

Background:

• Cancer is a leading global cause of mortality, often developing resistance to existing therapies.
• Simultaneous inhibition of kinase and histone deacetylase (HDAC) enzymes presents a novel therapeutic avenue.
• Hybrid inhibitors combining kinase and HDAC targeting moieties are being explored to overcome drug resistance.

Purpose of the Study:

• To review the latest strategies in the development of hybrid kinase/HDAC inhibitors.
• To analyze current trends in the design of these novel therapeutic agents.
• To identify existing gaps in research for future drug development.

Main Methods:

• Review of recent scientific literature on hybrid kinase/HDAC inhibitors.
• Analysis of common structural motifs and targeted enzyme classes.
• Identification of design trends and therapeutic applications.

Main Results:

• Common trends include using heterocycle scaffolds (e.g., pyrimidine, quinazolines) for kinase inhibition and hydroxamic acids/benzamides for HDAC inhibition.
• Advances have been made in developing compounds targeting tyrosine kinase/HDAC, serine-threonine kinase/HDAC, and lipid kinase/HDAC.
• Specific examples of hybrid compounds targeting various kinase families and HDACs are discussed.

Conclusions:

• Hybrid inhibitors offer a promising strategy to combat cancer treatment resistance.
• Continued research into novel scaffolds and combinations is crucial for advancing this field.
• Identifying and addressing research gaps will accelerate the development of effective dual-action cancer therapies.